Abstract
Ribavirin is ineffective against hepatitis C virus as mono-therapy but is critical in attaining both early virologic response and sustained virologic response when combined with pegylated interferon. Ribavirin has significant dose-limiting toxicities, the most important of which is hemolytic anemia. Taribavirin is a ribavirin pro-drug, which targets the liver and has less incidence of anemia, and it may be a promising alternative to ribavirin in the future.
MeSH terms
-
Anemia, Hemolytic / chemically induced
-
Antiviral Agents / chemistry*
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use*
-
Carbamates / chemistry
-
Carbamates / pharmacology
-
Hepacivirus / drug effects
-
Hepatitis C / drug therapy*
-
Humans
-
IMP Dehydrogenase / antagonists & inhibitors
-
Mycophenolic Acid / analogs & derivatives
-
Mycophenolic Acid / pharmacology
-
Phenylurea Compounds / chemistry
-
Phenylurea Compounds / pharmacology
-
Ribavirin / adverse effects
-
Ribavirin / analogs & derivatives*
-
Ribavirin / chemistry
-
Ribavirin / pharmacology
Substances
-
Antiviral Agents
-
Carbamates
-
N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic acid tetrahydrofuran-3-yl ester
-
Phenylurea Compounds
-
Ribavirin
-
IMP Dehydrogenase
-
IMPDH1 protein, human
-
Mycophenolic Acid
-
taribavirin